IS4010A - Ónæmisvaldandi Glýkósamtengi - Google Patents

Ónæmisvaldandi Glýkósamtengi

Info

Publication number
IS4010A
IS4010A IS4010A IS4010A IS4010A IS 4010 A IS4010 A IS 4010A IS 4010 A IS4010 A IS 4010A IS 4010 A IS4010 A IS 4010A IS 4010 A IS4010 A IS 4010A
Authority
IS
Iceland
Prior art keywords
carbohydrate
immunogenic
peptide
glycosylation
tumor
Prior art date
Application number
IS4010A
Other languages
English (en)
Inventor
Jondal Mikael
Original Assignee
Ab Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9201338A external-priority patent/SE9201338D0/xx
Priority claimed from SE9202553A external-priority patent/SE9202553D0/xx
Priority claimed from SE9203897A external-priority patent/SE9203897D0/xx
Priority claimed from SE9301141A external-priority patent/SE9301141D0/xx
Application filed by Ab Astra filed Critical Ab Astra
Publication of IS4010A publication Critical patent/IS4010A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18Acyclic radicals, substituted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/605MHC molecules or ligands thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
IS4010A 1992-04-28 1993-04-27 Ónæmisvaldandi Glýkósamtengi IS4010A (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9201338A SE9201338D0 (sv) 1992-04-28 1992-04-28 New active compounds
SE9202553A SE9202553D0 (sv) 1992-09-07 1992-09-07 New active compounds ii
SE9203897A SE9203897D0 (sv) 1992-12-23 1992-12-23 New active compounds iii
SE9301141A SE9301141D0 (sv) 1993-04-06 1993-04-06 New active compounds iv

Publications (1)

Publication Number Publication Date
IS4010A true IS4010A (is) 1993-10-29

Family

ID=27484749

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4010A IS4010A (is) 1992-04-28 1993-04-27 Ónæmisvaldandi Glýkósamtengi

Country Status (19)

Country Link
US (2) US5807559A (is)
EP (1) EP0675733B1 (is)
JP (1) JPH07506358A (is)
CN (1) CN1096032A (is)
AT (1) ATE197903T1 (is)
AU (1) AU676679B2 (is)
CA (1) CA2134097A1 (is)
DE (1) DE69329735T2 (is)
DK (1) DK0675733T3 (is)
ES (1) ES2155070T3 (is)
GR (1) GR3035501T3 (is)
IL (1) IL105503A (is)
IS (1) IS4010A (is)
MA (1) MA22885A1 (is)
MY (1) MY108864A (is)
PT (1) PT675733E (is)
SI (1) SI9300223A (is)
TN (1) TNSN93045A1 (is)
WO (1) WO1993021948A1 (is)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083929A (en) * 1991-05-06 2000-07-04 The Biomembrane Institute Extended type 1 chain glycosphingolipids as tumor-associated antigens
DE4436164A1 (de) * 1994-10-10 1996-04-11 Hoechst Ag Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US6841543B1 (en) * 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
WO1998015286A1 (en) * 1996-10-08 1998-04-16 La Jolla Institute For Allergy & Immunology Carbohydrate-specific cytolytic t cells
ES2265162T3 (es) * 1997-03-27 2007-02-01 Institut Pasteur Carbohidrato glucopeptido de antigeno multiple, vacuna que comprende el mismo y su utilizacion.
US20070237785A1 (en) * 1997-03-27 2007-10-11 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
US7550146B2 (en) * 1997-04-16 2009-06-23 Sloan-Kettering Institute For Cancer Research Glycopeptide conjugates and uses thereof
JP4308918B2 (ja) 1997-04-16 2009-08-05 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ (2,6)−STエピトープクラスターを有するα−O−結合複合糖質、その製造方法および使用
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
EP1091751A4 (en) * 1998-03-25 2005-01-19 Sloan Kettering Institutefor C TRIMERIC OXYGENIC BINDING GLYCOPEPTIDE CONJUGATES, METHODS OF PREPARATION AND USE THEREOF
JP2002509716A (ja) 1998-03-31 2002-04-02 ユニバーシティ テクノロジー コーポレイション テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
US6573245B1 (en) * 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
US20030091546A1 (en) * 1998-11-12 2003-05-15 Barber Jack R. Methods of suppressing immune response by gene therapy
US7854934B2 (en) * 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
JP5111705B2 (ja) 1999-08-20 2013-01-09 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ 新規な複合多糖、グリコアミノ酸、これらへの中間体、及びこれらの使用
US7824687B2 (en) 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
JP2007516157A (ja) * 2003-02-06 2007-06-21 トリペップ アクチ ボラゲット グリコシル化された抗原/抗体又はリガンド/受容体特異性交換体
WO2005077411A2 (en) * 2004-02-10 2005-08-25 Innate Pharma Composition and method for the treatment of carcinoma
WO2006121803A1 (en) 2005-05-05 2006-11-16 Sensient Flavors Inc. Production of beta-glucans and mannans
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
JP5792630B2 (ja) 2009-01-28 2015-10-14 エピミューン,インコーポレイティド Pan−dr結合ポリペプチドおよびその使用
CN103038343A (zh) 2010-03-23 2013-04-10 英特瑞克斯顿股份有限公司 条件表达治疗蛋白的载体,包含所述载体的宿主细胞,及其应用
EP2500033A1 (en) 2011-03-17 2012-09-19 Institut Pasteur Method for preparing muliple antigen glycopeptide carbohydrate conjugates
CA2837214C (en) 2011-06-28 2021-06-01 Inovio Pharmaceuticals, Inc. A minimally invasive dermal electroporation device
EP2606897A1 (en) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Methods and compositions for the treatment of diseases caused by enveloped viruses
JP7210534B2 (ja) 2017-07-12 2023-01-23 ザ・ボード・オブ・トラスティーズ・オブ・ザ・リーランド・スタンフォード・ジュニア・ユニバーシティ H3k27m変異を有するがんの処置のための組成物および方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2004744B (en) * 1977-09-28 1982-05-26 Sanderson A R Immonulogical preparations
CA1335883C (en) * 1986-07-08 1995-06-13 Bryan Michael Longenecker Enhancement of the cellular immune response
AU634153B2 (en) * 1988-02-01 1993-02-18 Wyeth Holdings Corporation T-cell epitope as carriers molecule for conjugate vaccines
AU4030989A (en) * 1988-02-12 1989-09-06 Regents Of The University Of California, The Use of synthetic peptides to generate and manipulate cellular immunity
US5229289A (en) * 1988-03-11 1993-07-20 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
CA1337403C (en) * 1988-03-28 1995-10-24 Biomembrane Institute (The) Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones
EP0482068A1 (en) * 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
AU6272190A (en) * 1989-08-28 1991-04-08 Pierce Chemical Company Cationized carriers for immunogen production
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.

Also Published As

Publication number Publication date
PT675733E (pt) 2001-05-31
EP0675733A1 (en) 1995-10-11
IL105503A0 (en) 1993-08-18
AU676679B2 (en) 1997-03-20
DK0675733T3 (da) 2001-05-07
MA22885A1 (fr) 1993-12-31
CN1096032A (zh) 1994-12-07
DE69329735T2 (de) 2001-08-02
JPH07506358A (ja) 1995-07-13
TNSN93045A1 (fr) 1994-03-17
DE69329735D1 (de) 2001-01-11
CA2134097A1 (en) 1993-11-11
SI9300223A (en) 1994-03-31
WO1993021948A1 (en) 1993-11-11
GR3035501T3 (en) 2001-06-29
AU4274693A (en) 1993-11-29
EP0675733B1 (en) 2000-12-06
US5807559A (en) 1998-09-15
ES2155070T3 (es) 2001-05-01
US6033669A (en) 2000-03-07
MY108864A (en) 1996-11-30
IL105503A (en) 1999-05-09
ATE197903T1 (de) 2000-12-15

Similar Documents

Publication Publication Date Title
IS4010A (is) Ónæmisvaldandi Glýkósamtengi
BR9303469A (pt) Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas
ES2056215T3 (es) Composiciones de detergente.
FI914607A (fi) Farmaceutisk blandning i gelform i en dispenserfoerpackning.
DE69808130D1 (de) Adamantan-derivate
ATE68960T1 (de) Shampoo-praeparate.
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
EP0372752A3 (en) Cd4 polypeptide derivatives
EP1003526A4 (en) COVALENT-TIED N, O-CARBOXYMETHYLCHITOSAN AND ITS USE
FI910222A0 (fi) Anti-inflammatoriska 4-aminofenolderivat.
IT8920898A0 (it) Uso di sucralfato gel umido per il trattamento di ulcere del derma e come veicolo di farmaci ad attivita' topica.
DE69106361T2 (de) Einschlusskomplex von nimesulide mit cyclodextrinen.
ATE31023T1 (de) Pharmazeutische zubereitung mit gehalt an gereinigtem fibrinonectin.
IL122700A0 (en) Pyranosyl conjugates for delivery of active moieties
JO1766B1 (en) Effective new compounds
TW332816B (en) Peptide and carbohydrate
NO932823L (no) Bicyklopolyazamakrocyklofosfonsyrer, deres komplekser og konjugater, for anvendelse som kontrastmidler og fremgangsmåter for deres fremstilling
NO961204D0 (no) Triaryletylenderivater for anvendelse innen terapi
IT8820245A0 (it) Palmitoil_fruttosio_1,6_difosfato, suo uso terapeutico e relativi metodi di preparazione.
FR2652266B1 (fr) Vaccin protecteur contre l'hemophilose porcine.
IT8720800A0 (it) Composto attivo nella terapia carciovascolare.
TH13666A (th) สารประกอบออกฤทธิ์ชนิดใหม่
ITVI950066A0 (it) Procedimento per la fabbricazione di pannelli per l'impiego nel setto-re del mobile, a basso costo e atossico
NO884941D0 (no) Konjugat av metallothionein eller et metallothioneinfragment og et maalsoekende biologisk aktivt molekyl, som er anvendelig som mellomprodukt ved fremstilling av lignende merkede konjugater.
IT1229566B (it) Gel di antracicline e loro uso terapeutico.